<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151213">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01724489</url>
  </required_header>
  <id_info>
    <org_study_id>2012-D-002574</org_study_id>
    <nct_id>NCT01724489</nct_id>
  </id_info>
  <brief_title>Study of Growth Hormone and Bone in Obesity</brief_title>
  <official_title>Skeletal Physiology Dysregulation in Obesity: The Role of Growth Hormone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is an important risk factor for osteoporosis and fractures. With the growing
      prevalence of obesity in the U.S., understanding the pathophysiology of bone loss in this
      population is of importance to public health. Growth hormone (GH) is a critical mediator of
      bone homeostasis and is markedly reduced in obesity. Our preliminary data suggest an
      important role for the GH/insulin-like growth factor 1 (IGF-1) system in the pathogenesis of
      bone loss in obesity. The development of novel imaging techniques provides an opportunity to
      investigate the effects of GH on skeletal structure and strength, which will provide
      insights into the pathogenesis of obesity related bone loss. Understanding the
      pathophysiology of bone loss in obesity may help identify new treatment targets for this
      important complication. The investigator hypothesizes that low-dose GH administration for 18
      months will improve skeletal health.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>baseline and 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in BMD over 18 months in the GH vs placebo group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Obesity</condition>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Growth Hormone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Growth Hormone is Genotropin, provided by Pfizer Inc. It is self administered daily for 18 months using a 5 mg injection pen device. Dose will be titrated based on IGF-1 levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be provided by Pfizer Inc.  It will appear identical to active growth hormone and will be administered in the same manner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth hormone</intervention_name>
    <arm_group_label>Growth Hormone</arm_group_label>
    <other_name>Genotropin (Pfizer Inc.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18-65 and generally healthy

          -  BMI ≥ 25 kg/m2

          -  Bone mineral density (BMD) T score ≤ -1.0 and &gt; -2.5 (as measured by DXA)

        Exclusion Criteria:

          -  For women: amenorrhea for 3 months, pregnancy or breastfeeding, polycystic ovary
             syndrome

          -  History of diabetes mellitus, cancer or other serious chronic disease

          -  Use of osteoporosis medications

          -  Anemia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miriam Bredella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anu V Gerweck, NP</last_name>
    <phone>617-724-1837</phone>
    <email>avgerweck@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anu V Gerweck, NP</last_name>
      <phone>617-724-1837</phone>
      <email>avgerweck@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>November 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Karen Klahr Miller, MD</investigator_full_name>
    <investigator_title>Director, Neuroendocrine Research Program in Women's Health</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
